← Back to all trials
Completed
NCT04964466
Release Kinetics in PRF Versus GEM21S With and Without Bone Substitutes: An In Vitro Analysis
Conditions: Bone Loss
Sex: All
Ages: 18 Years – 99 Years
Healthy volunteers: Yes
Enrollment: 5
Sponsor: University of Alabama at Birmingham
Location: University of Alabama at Birmingham Birmingham Alabama
Summary
This study is seeking to evaluate that platelet-derived growth factor-BB (PDGF-BB) is a proven wound healing and osteogenic protein that plays a critical role in wound healing and previous research has demonstrated a non-linear response where higher dosages produced less effect. As Platelet Rich Fibrin (PRF) contains numerous platelets, it contains PDGF-BB, but at levels lower than in the commercially available product and with inter-individual variation, GEM21S. To achieve both ideal handling and achieve ideal levels of PDGF-BB, there is a rationale to add GEM 21S recombinant human platelet-derived growth factor-BB (rhPDGF) to a bone graft prior to making "sticky bone".
Eligibility Criteria
Inclusion Criteria:
* English speaking
* At least 18 years old
* Able to read and understand informed consent document
* Systemically healthy, non-smoker, no medications
Exclusion Criteria:
* Non-English speaking
* Less than 18 years old
* Smokers/tobacco users (\>10 cigarettes/day)
* Patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting healing
Source: ClinicalTrials.gov (NCT04964466). StuddyBuddy aggregates publicly available trial information.